Morpholino Database

Search By For Use * as a wildcard character (e.g. "BMP*"). For Tips on search see Search FAQs.

Morpholino Summary

General Information

Morpholino name:

alox12

Morpholino sequence:

CTCTGTGGTGTGGTGGTGAAAATCT
Find in Genbank

Target name:

alox12

Target sequence: (Morpholino Target and ATG)
Search in Genbank Search in Ensembl

CAGACACAGTTACTGTGTGTGCTTAAGGCTGACATGAAAGAAGGAAACTAGGGGTGGCTGAGAAAAAAA ATAAAAAAGTCACAGAGACATAAAAGAGCCAACAAAAAAACTACTGCTGAGAAGAAGAAACACGCATCAG ATTTTCACCACCACACCACAGAGAATAGAGAAGAAGAAAACGATCAATTTCATCACCACACTACTGAGAA AAAGATGGAGTACAAAGTGACAGTGGCCACCGGGACTTCTGAATATTCAGGGACCAATAATTATGTGTAC GTGACTCTGATTGGAGAGAAAGGAAAGAGCGAGAGGACGCTGCTGGACAATCCTGGCCTGGACTTCTGCA GAGGAGCTGTGGATGATTACATAGTTAAAAGCGATACTGATTTGGGCCCCCTGATTCTGGTGCGACTGGA GAAGCACAAGTACTTCATAGAAGACAACTGGTTCTGCCGCTACGTGAAAGTCAGTGTACCTGGAGAAAGA TGTTGTTACACATTTCCTTGTTACCGCTGGCTTGTGGGAGATGGAGTGTTTGTAGAGCTCAGAGAAGGCA CAGCCAAAAAGCTGAGCGAAGACAGTCTGCCGCTGGAAATGGCTCACAGACAATCAGAGCTTCAGGAGAG GCAGAAAACATACAGATGGGTTGCATGGGCTCCTGGCATTCCCAAATGCATTGATGCAAAAAGTGAAGCT GATCTGCCCCAGGACGCTCGATTTGACAACGAGAAACGCAGTGATTTTGAGGGATCTCTTCATTATGCTC TGTTGGAGCTCTCACTGAAAAAATTGGCAATCCGGTTTGGAAAGTCCTGGAGTGACCTGGAGGATTTCAG GAGGATCTTCTGGAAACTAAGAAGCCCCATAGCTGAATACACCATGGAGCACTGGAAAGAAGACTGGTTT TTTGCTTACCAGTTCTTGAACGGCTCAAACCCACGGAATATCACCAGATTGAAAAAGGTGCCTTCAAACT TCCTTGTCACTGGAGATATGGTTCAGTCATCTCTGATACCCACAACCACTCTGAATGAGGAACTCAAGAA AGGAAACATTTTCCTGGTTGATCATGCAATACTGGATGGGATTCCTGCCAATGTAATCAGAAACAGCCCC CAGTATATTGCTGCCCCACTCTGCTTACTGTATGAACACCCTGAGAAAGGGCTCATTCCCATCGCCATAC AGCTTGAACAGAAACCTGATAAGGACACACCCGTATTTCTGCCCAGTGATCCACCTCTGGCCTGGTTGTT GGCTAAGATGTGGGTTCGTCATGCTGAATTCCAGGTCTTTCAGTTGTTGTCTCATCTGCTGCGCACACAT TTGATGGTAGAAGTGATCTGTGTGGCCACACTACGGCAGCTGCCAGCTGTTCACCCCATATATAAGCTCT TGACTCCACACTTGAGGTACACGCTGGAGATTAACTGTCGTGGCAGAACACAGCTCCTCTCTCCAGAGGG CATCTTCAAAAGGGTGGTGTCCACAGGTGGAGAAGGTCTCTTGATATTGGCTCAAAGGGAGTATAAAGTT CTGACCTATCGCTCTCTTCAGCCTAAATTTGACTTCTTGGACAGAGGGGTTACTAAAGTGAAAGGCTATG TTTACAGAGACTACTCTCTGATGCTGTGGGATGTGATTCAGAATTTTGTTTCAGGAATTGTTTCCCTGTA CTACCAGTGTGACAGTGACGTGCAAGAGGACTCTGAGCTTCAGGCCTGGATTCATGATGTGGCTGTGGAA GGCTTTGTGGATGTTCCTGAATTTGGCCTGGCCAGTGATATGAAGACAAAAGAGGAGCTGATCACTCTGT TAAGTGTGGCGATCTTCACCAGCACAGCACAACATGCTGCCACAAACAACGGACAGTTTGACTGGTGCGC TTGGGTACCCAACACCCCCTGCACCATGAGACACCCCCCACCAAGAGATAAAGATGCAGTGACCATGGAA ATGATTATGGACACGCTGCCTGACATCAGCCAGTCCTGTGTGCAGATGGCCATCACATGGCATTTGGGCC GGGCACAGCCTGATGCGATCCCAATGGGCCAGTATGTGGAGCAGTACTTCACTGAACCCGCTGCTTTGAA GGTGATTGACAAATTCAGGAAAGAGCTGAAAGAACTGGAGGACAAGATAATGGCCCAGAACGAGGGACTC GAACTTCAGTACCTTTACCTTTGTCCAAGCCGCATGGAAAACAGCATCACTATTTAGAGACAAAAACATA AACACTACCTGACAAAAGTCGTCGCCTATCCAAGTATTAGGAGCAGCAAATAGTGGCTTGACTTCTGGTT GATCATTTGGTATCAGATGTGGCTTATATGAAAGGCAAAGGCCTCTAGATTACACTTATTTTACCAAAAT AAAACATGATCCTGCCTTGATTTTTAATTGTTTAATTAGGACAGTAAGGTCTGACTTTGCTTGGACAGTC TTGTTGCGTAATGTGCAGAAATAATGTCAAAGAAAGCGTTCTTGCAGGACTCCTCGAATCATCAAGATTC TTTGAATTCATCTTCAATGCCTTCTCCTTCATCTTACCCCAGACATGCTCAATAATGTTCTTATCTGGTG ACTGGGCTGGCCAATCTTGGAGCACCTTGACCTTCTTTGCTTTCAGGAACTTTGTGGAGGCTTAAGTATG AGAAGGAGCGCTATGAAGAATAATAGCACAGAATCTTCTGCCAAATCTACCTTCTGCCACTTTTCCAAAT GATCGATTGGAAGTCAAGTTATTATTTGTTGCTATTACAACTGGGATCGACGGCAATTCTTTTGTCAGGT AGAGTACATGTAAATACGCATTTGTACCATCTTTTCCAGTCAATGACTTGCTCAGCAATGGGATCTATCA CAGCATGTGTCAAAATTGTAATATATATCATTTGAAACTTTGTAAAGCATCAGTACGTAAAGCTTTTTTA TATTCACTTTAGTGAACCGTTTTTTTTAGTTTGATTTTAAACTAATAATGTGCATTGAACTGTTTGAACG GAACTTTCTATGAGCTGTTTCTGTGTATATTTTACCACTGTATGCATCAGCTTTAGAAAACACACGTTTT ATATTTAATACATTTTTGTTTCAGATGCAGACAATGCATCATCACTAAACTTTAATCTGTGTACATATGC ATGCATTGGCTTTTCATTTGTCCATTGCAAATAAAGATTTTTGTTAACACTTTAGGTCACAATTTATTTT ATTAACTACTCGCCTATTACCTGCCTATTATTAAGATATTAACTGTTCATTAGTGGTTATGAAGTATGAT CTTATTCTGCATCCCCAATTCTTCCCTTAAACTAAACTCAACTTCTACCTTACTATGAATAAACAGTTAA TTAGTCGTTCATTAGGGTAGTAGTGTTAGTTAATGGTTTGTTAATATCGTGAAGTATGACCTAAAGTGTC ACCAAACATTTTTATTTCATATTTTAGTGTTGTATTCTTATTTTACTTGTAATATTTTCCTGCATATCTT TATCTGTGGACACCATTCATTAAAAAATTATAAATCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

Gene targeted:

Synonyms:

Comments:

Reference:

Survival Curve:	Normality Curve:

Note: When more than one data point existed per dose an average was used. p53 morpholino co-injections were used to minimize non-specific toxicity effects (Robu et al. PLoS Genetics 2007)

Screens Performed (number of tests):	Defects Observed:
	None

Images